Blackstone, a private investment platform that invests across the life-cycle of companies and products within the key life science sectors, and Alnylam Pharmaceuticals, one the leading RNAi therapeutics companies, today announced the closing of $150 million R&D funding to advance RNAi therapeutics for […]